General Information of Drug (ID: DM3MSZN)

Drug Name
5,N-Dihydroxythalidomide Drug Info
Synonyms
5,N-Dihydroxythalidomide; 5,1'-Dihydroxythalidomide; 5,1'-Dihydroxy thalidomide; 5,1'-Dihydroxy thalidomide, (+/-)-; CHEMBL479546; 1H-Isoindole-1,3(2H)-dione, 5-hydroxy-2-(1-hydroxy-2,6-dioxo-3-piperidinyl)-; 478785-12-5
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10356851
CAS Number
CAS 478785-12-5
TTD Drug ID
DM3MSZN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug(s) Targeting Progesterone receptor (PGR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [2]
Desogestrel DM27U4Y Contraception QA21 Approved [3]
Ulipristal DMBNI20 Contraception QA21 Approved [4]
Etonogestrel DMKA8J4 Contraception QA21 Approved [5]
Megestrol DMDH9KX Breast cancer 2C60-2C65 Approved [6]
Segesterone acetate; ethinyl estradiol DMFEGB0 Contraception QA21 Approved [7]
Norgestimate DMYP4XC Acne vulgaris ED80 Approved [5]
Dydrogesterone DMAKIDV Menstrual disorder GA20.3 Approved [8]
Medroxyprogesterone DMBGWPH Solid tumour/cancer 2A00-2F9Z Approved [8]
Ethynodiol Diacetate DMZM84R Contraception QA21 Approved [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Progesterone receptor (PGR) TTUV8G9 PRGR_HUMAN Inhibitor [1]

References

1 Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. Bioorg Med Chem. 2008 Jul 15;16(14):7046-54.
2 Clinical pipeline report, company report or official report of lipocine.
3 Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
4 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
5 Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
6 Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
7 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
8 Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
9 Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.